CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead ... - Yahoo Finance
| CEROW Stock | 0.01 0 14.29% |
Slightly above 60% of CERo Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading CERo Therapeutics Holdings stock suggests that many investors are alarmed at this time. CERo Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CERo Therapeutics' earnings reports, geopolitical events, and overall market trends.
CERo |
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead ... Yahoo Finance
Read at news.google.com
 |
CERo Therapeutics Fundamental Analysis
We analyze CERo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
CERo Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
CERo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CERo Therapeutics stock to make a market-neutral strategy. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics with similar companies.
Peers
CERo Therapeutics Related Equities
| ABCL | Abcellera Biologics | 5.17 | ||||
| ARDX | Ardelyx | 2.77 | ||||
| MNMD | Mind Medicine | 1.99 | ||||
| FRHC | Freedom Holding | 0.02 | ||||
| IPXXU | Inflection Point | 1.11 | ||||
| SMMT | Summit Therapeutics | 2.88 | ||||
| VALN | Valneva SE | 8.28 |
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.